Adjuvant chemotherapy for colon cancer

Current Oncology Reports

Volumn 3, Issue 2, 2001, Pages 94-101

  Kumar, Shaji K ^a   Goldberg, Richard M ^a  

^a MAYO CLINIC CANCER CENTER   (United States)

Author keywords

Colon Cancer; FUDR; Leucovorin; Levamisole; Raltitrexed

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; FLUOROURACIL; FOLINIC ACID;

ADJUVANT CHEMOTHERAPY; COLON TUMOR; HUMAN; LIVER TUMOR; METASTASIS; PATHOLOGY; PROGNOSIS; REVIEW; RISK FACTOR; TUMOR RECURRENCE;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RISK FACTORS;

EID: 0035286598     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-001-0007-6     Document Type: Article

References (47)

1. Li MC, Ross ST: Chemoprophylaxis for patients with colorectal cancer: prospective study with five-year follow-up. JAMA 1976, 238:2825–2828. DOI: 10.1001/jama.235.26.2825
2. Greenlee R, Murray T, Bolden S, Wingo P: Cancer Statistics, 2000. CA Cancer J Clin 2000, 50:7–33.
3. Higgins GA Jr, Amadeo JH, McElhinney J, et al.: Efficacy of prolonged intermittent therapy with combined 5-fluorouracil and methyl-CCNU following resection for carcinoma of the large bowel: a Veterans Administration Surgical Oncology Group report. Cancer 1984, 53:1–8. DOI: 10.1002/1097-0142(19840101)53:1<1::AID-CNCR2820530102>3.0.CO;2-L
4. Buyse M, Zeleniuch A, Chalmers T: Adjuvant therapy of colorectal cancer. JAMA 1988, 259:3571–3578. DOI: 10.1001/jama.259.24.3571
5. Wolmark N, Fisher B, Rockette H, et al.: Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst 1988, 80:30–36. DOI: 10.1093/jnci/80.1.30
6. Verhaegen H, DeCree J, DeCock, et al.: Levamisole therapy in patients with colon cancer. In Immunotherapy of Human Cancer. Edited by Terry W, Rosenberg S. New York: Elsevier; 1982:225–229.
7. Borden E, Davis T, Crowley J, et al.: Interim analysis of a trial of levamisole and 5-fluorouracil in metastatic colorectal carcinoma. In Immunotherapy of Human Cancer. Edited by Terry W, Rosenberg S. New York: Elsevier; 1982:231–235.
8. Laurie JA, Moertel CG, Fleming TR, et al.: Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil: the North Central Cancer Treatment Group and the Mayo Clinic [see comments]. J Clin Oncol 1989, 7:1447–1456.
9. Metzger U: Adjuvant therapy for colon and rectal cancer: NIH Consensus Development Conference. Eur J Cancer 1990, 26:753–755. DOI: 10.1016/0277-5379(90)90136-H
10. Moertel CG, Fleming TR, Macdonald JS, et al.: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995, 122:321–326.
11. Cascinu S, Catalano V, Latini G, et al.: A randomized trial of adjuvant therapy of stage III colon cancer: levamisole and 5-Fluorouracil versus 5-Fluorouracil alone [abstract]. Proc ASCO 1999, 18:923.
12. Moertel CG, Fleming TR, Macdonald JS, et al.: Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes’ B2 colon cancer. J Clin Oncol 1995, 13:2936–2943.
13. Keyomarsi K, Moran R: Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemic cells. Cancer Res 1986, 46:5229–5235.
14. Rustum Y, Trave F, Zakrzewski S, et al.: Biochemical and pharmacologic basis for potentiation of 5-fluorouracil action by leucovorin. Natl Cancer Inst Monogr 1987, 5:165–170.
15. Wolmark N, Rockette H, Fisher B, et al.: The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993, 11:1879–1887.
16. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators: Efficacy of adjuvant fluorouracil and folinic acid in colon cancer [see comments]. Lancet 1995, 345:939–944. DOI: 10.1016/S0140-6736(95)90696-7
17. O’Connell MJ, Mailliard JA, Kahn MJ, et al.: Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997, 15:246–250.
18. Wolmark N, Rockette H, Mamounas E, et al.: Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999, 17:3553–3559. The NSABP C-04 compared the efficacy of leucovorin-modulated 5-fluorouracil (5-FU) with that of fluorouracil and levamisole or with a combination of all three drugs given as adjuvant therapy after resection of stage II and III colon cancer. The 5-FU/leucovorin combination had a slight advantage over the combination with levamisole in terms of both overall and disease-free survival, but addition of levamisole to this combination did not add any further benefit. This study confirmed the results of earlier trials regarding the efficacy of the 5-FU/leucovorin combination.
19. Haller D, Catalano P, Macdonald J, et al.: Fluorouracil (FU), Leucovorin (LV) and Levamisole (LEV) adjuvant therapy for colon cancer: five year final report of INT-0089. Proc ASCO 1998, 17:256a(982).
20. Eisenberg B, DeCosse J, Harford F, et al.: Carcinoma of the colon and rectum: the natural history reviewed in 1,704 patients. Cancer 1982, 49:1131–1134. DOI: 10.1002/1097-0142(19820315)49:6<1131::AID-CNCR2820490611>3.0.CO;2-T
21. Floyd C, Sterling C, Cohn IJ: Cancer of the colon, rectum and anus. Review of 1687 cases. Ann Surg 1966, 163:829–837. DOI: 10.1097/00000658-196606000-00003
22. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators: Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer [see comments]. J Clin Oncol 1999, 17:1356–1363. In this study, patients with B2 colon cancer were entered into five separate trials comparing the combination of 5-FU and leucovorin to observation and were analyzed together in an effort to clarify the role of adjuvant chemotherapy. The authors failed to demonstrate any meaningful benefit for the adjuvant chemotherapy. This is the opposite conclusion to that reached by another study looking at pooled data from the NSABP trials.
23. Mamounas E, Wieand S, Wolmark N, et al.: Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04) [see comments]. J Clin Oncol 1999, 17:1349–1355.
24. Zoetmulder F, Taal B, VanTinteren H: Adjuvant 5FU plus levamisole improves survival in stage II and III colonic cancer, but not in rectal cancer: interim analysis of the Netherlands Adjuvant Colorectal Cancer Project (NACCP). Proc ASCO 1999, 18:1021.
25. Halling KC, French AJ, McDonnell SK, et al.: Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers [see comments]. J Natl Cancer Inst 1999, 91:1295–1303. DOI: 10.1093/jnci/91.15.1295
26. Liefers GJ, Cleton-Jansen AM, van de Velde CJ, et al.: Micrometastases and survival in stage II colorectal cancer [see comments]. N Engl J Med 1998, 339:223–228. DOI: 10.1056/NEJM199807233390403
27. Saha S, Wiese D, Beutler T, et al.: Accuracy of diagnosis of micrometastasis in colorectal cancer by sentinel lymph node mapping technique [abstract]. Proc ASCO 1999, 18:908.
28. Taylor I, Machin D, Mullee M, et al.: A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer. Br J Surg 1985, 72:359–363. DOI: 10.1002/bjs.1800720509
29. Wolmark N, Rockette H, Wickerham DL, et al.: Adjuvant therapy of Dukes’ A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02 [see comments]. J Clin Oncol 1990, 8:1466–1475.
30. Beart RW Jr, Moertel CG, Wieand HS, et al.: Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion: a study of the Mayo Clinic and the North Central Cancer Treatment Group. Arch Surg 1990, 125:897–901.
31. Nitti D, Wils J, Sahmoud T, et al.: Final results of a phase III clinical trial on adjuvant intraportal infusion with heparin and 5-fluorouracil (5-FU) in resectable colon cancer (EORTC GITCCG 1983–1987). European Organization for Research and Treatment of Cancer. Gastrointestinal Tract Cancer Cooperative Group. Eur J Cancer 1997, 33:1209–1215. DOI: 10.1016/S0959-8049(97)00052-X
32. Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies: Liver Infusion Meta-analysis Group. J Natl Cancer Inst 1997, 89:497–505. Report on mortality and recurrence from 10 randomized trials in which continuous postoperative PVI of cytotoxic drugs was compared with no further treatment involving about 4000 patients. The results demonstrate a minimal improvement in survival at 5 years. This analysis of a large number of patients failed to substantiate the promising results seen in the initial study.
33. Fong Y, Cohen AM, Fortner JG, et al.: Liver resection for colorectal metastases. J Clin Oncol 1997, 15:938–946.
34. Sugarbaker PH, Gianola FJ, Speyer JC, et al.: Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer. Surgery 1985, 98:414–422.
35. Kemeny N, Huang Y, Cohen AM, et al.: Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999, 341:2039–2048. Patients were randomized after resection of hepatic metastases to receive six cycles of hepatic arterial infusion with floxuridine and intravenous fluorouracil, or 6 weeks of similar systemic therapy alone. The actuarial rate of overall survival at 2 years was 86% in the group treated with local plus systemic chemotherapy and 72% in the group given systemic therapy alone (P=0.03) This is the first study to show a definite benefit for hepatic artery chemotherapy in reducing recurrence rate after metastasis resection. DOI: 10.1056/NEJM199912303412702
36. Kemeny M, Adak S, Lipsitz B, et al.: Results of the Intergroup prospective randomized study of surgery alone versus continuous hepatic artery infusion of FUDR and continuous systemic infusion of 5FU after hepatic resection of colorectal liver metastasis [abstract]. Proc ASCO 1999, 18:1012.
37. Pitot HC: US pivotal studies of irinotecan in colorectal carcinoma. Oncology 1998, 12(suppl 6):48–53.
38. Cunningham D: Current status of colorectal cancer: CPT-11 (irinotecan), a therapeutic innovation. Eur J Cancer 1996, 32A(suppl 3):S1-S8. DOI: 10.1016/0959-8049(96)00290-0
39. Van Cutsem E, Peeters M, Verslype C, et al.: The medical treatment of colorectal cancer: actual status and new developments. Hepatogastroenterology 1999, 46:709–716.
40. de Gramont A, Figer A, Seymour M, et al.: A randomized trial of leucovorin and 5-fluorouracil with or without oxaliplatin in advanced colorectal cancer. Proc ASCO 1998, 17:257a.
41. Meta-analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998, 16:301–308.
42. Pazdur R: Phase II study of UFT plus leucovorin in colorectal cancer. Oncology 1997, 54(suppl 1):19–23. DOI: 10.1159/000227741
43. Smith R, Wickerham DL, Wieand HS, et al.: UFT plus calcium folinate vs. 5-FU plus calcium folinate in colon cancer. Oncology 1999, 13(suppl 3):44–47.
44. Van Cutsem E, Peeters M: Developments in fluoropyrimidine therapy for gastrointestinal cancer. Curr Opin Oncol 1999, 11:312–317. DOI: 10.1097/00001622-199907000-00012
45. Sato A, Kurihara M, Horikoshi N, et al.: Phase II study of raltitrexed (Tomudex) in chemotherapy-pretreated patients with advanced colorectal cancer: Tomudex Cooperative Study Group. Anticancer Drugs 1999, 10:741–748. DOI: 10.1097/00001813-199909000-00008
46. Van Cutsem E: Raltitrexed (Tomudex) in combination treatment for colorectal cancer: new perspectives. Eur J Cancer 1999, 35 (suppl 1):S1-S2. DOI: 10.1016/S0959-8049(99)00040-4
47. Riethmuller G, Holz E, Schlimok G, et al.: Monoclonal antibody therapy for resected Dukes’ C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998, 16:1788–1794. Patients with resected Dukes’ C colorectal cancer were randomized to infusions of 17-1A antibody, 500 mg postoperatively, followed by four monthly doses of 100 mg, or to observation. At 7 years, there was a reduction in overall mortality by 32% (P=0.01) and in the recurrence rate by 23% (P=0.07). This is one of the few studies showing this magnitude of benefit with immunotherapy in the adjuvant setting.